Respiratory Diseases: A Clinical Guide for the Indian Setting

1. Pulmonary Tuberculosis (PTB)

Epidemiology in India

• Park's Textbook of Preventive and Social Medicine

Clinical Features

• Primary TB: Dense consolidation, middle and lower lobe predominance
• Reactivation TB (most common in adults): Cavitary disease in apical/posterior segments of right upper lobe and apical-posterior left upper lobe; tree-in-bud opacities (endobronchial spread); fibrotic scars; calcification; miliary pattern with hematogenous spread
• Goldman-Cecil Medicine

• Pleural TB: Exudative pleural effusion, pleuritic chest pain; occurs 3-6 months post-primary infection
• Miliary TB: 1-2 mm granulomatous nodules in lungs, liver, bone marrow, kidney, adrenals, spleen; choroidal tubercles on fundoscopy; hepatomegaly; lymphadenopathy
• Lymph node TB: Most common extrapulmonary site in India
• TB meningitis, spine (Pott's disease), genitourinary TB also prevalent

• Lower smear positivity, less cavitation, more dissemination
• Chest X-ray may be normal despite smear-positive disease; CT more sensitive
• Goldman-Cecil Medicine

Diagnosis in Indian Setting

Treatment - NTEP (National Tuberculosis Elimination Programme)

• Intensive phase (2 months): Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E) - i.e., 2HRZE
• Continuation phase (4 months): HR - i.e., 4HR
• Total duration: 6 months for most pulmonary TB

• Traditional regimen: At least 18-24 months; second-line drugs (fluoroquinolones, injectable aminoglycosides, linezolid, bedaquiline)
• Bedaquiline + pretomanid + linezolid (BPaL) - 6-month oral regimen now recommended by WHO for XDR-TB and eligible MDR-TB
• MDR-TB treatment costs 30 times more than drug-sensitive TB
• 147 DR-TB Centres (DR-TBCs) established across India by 2017; decentralized "test and treat" approach

• Totally Drug-Resistant TB (TDR-TB) has been described in isolated Indian studies
• Treatment failure is defined by positive sputum culture at 4 months
• NEVER add a single drug to a failing regimen (promotes further resistance)
• Park's Textbook of Preventive and Social Medicine; Goldman-Cecil Medicine

Prognosis

• With DOTS and drug-sensitive disease: >85% cure rate is the NTEP target; treatment success broadly achievable
• MDR-TB: Poor outcomes; high fatality especially with XDR-TB + HIV co-infection
• Persistent hypercapnia in TB-destroyed lungs predicts poor survival
• NTEP goal: End TB by 2025 (India's target, 5 years ahead of WHO's 2030 goal); progress is ongoing but challenges remain

2. COPD (Chronic Obstructive Pulmonary Disease)

Epidemiology in India

Clinical Features

• Diagnosis: Post-bronchodilator FEV1/FVC < 0.70
• GOLD 1 (Mild): FEV1 ≥80%; GOLD 2 (Moderate): 50-79%; GOLD 3 (Severe): 30-49%; GOLD 4 (Very Severe): <30%
• GOLD 2 (moderate) carries ~11% 3-year mortality; GOLD 4 carries ~24% 3-year mortality
• Textbook of Family Medicine; Murray & Nadel's Textbook of Respiratory Medicine

Treatment

• Smoking cessation (most effective intervention)
• Biomass fuel reduction / clean cooking stoves - critical Indian-specific intervention
• Pulmonary rehabilitation (limited access in India)
• Vaccination (influenza, pneumococcal)

• Triggered by viral infections, bacteria (H. influenzae, S. pneumoniae, Moraxella catarrhalis), air pollution spikes
• Treatment: Bronchodilators, short-course steroids (prednisolone 40mg x 5 days), antibiotics if purulent sputum/fever, oxygen (controlled - target SpO2 88-92% to avoid hypercapnic drive suppression), NIV if hypercapnic

Prognosis

• Persistent hypercapnia = poor prognostic marker; shorter survival vs. normocapnia
• Persistent hypercapnia post-exacerbation associated with excess mortality and early rehospitalization
• In India, prognosis worsened by late diagnosis, limited access to spirometry, and ongoing biomass exposure

3. Bronchial Asthma

Epidemiology in India

Clinical Features

• Episodes of wheeze, dyspnea, chest tightness, cough - often nocturnal/early morning
• Largely reversible airflow obstruction (key distinction from COPD)
• Triggers in India: dust, pollution, smoke, infections (especially respiratory viruses), cold air, exercise, foods/preservatives
• History of atopy (allergic rhinitis, eczema), family history

• Intermittent, Mild persistent, Moderate persistent, Severe persistent - based on symptom frequency, nocturnal symptoms, PEFR/FEV1

• Early-childhood onset favors asthma; mid-life onset + smoking/biomass exposure favors COPD
• Reversibility on spirometry (>12% and >200mL post-bronchodilator) = asthma
• Overlap syndrome (ACOS) common in India, especially in elderly smokers with prior asthma history

Treatment (Stepwise - GINA)

• Inhaler technique compliance is poor; device education is critical
• Metered-dose inhalers (MDIs) remain the mainstay; dry powder inhalers (DPIs) increasingly available
• Nebulizers widely used in acute settings and resource-limited rural areas
• Oral corticosteroids overused due to limited ICS access
• Ipratropium (anticholinergic) adds benefit in moderate-severe acute exacerbations

• Nebulized salbutamol + ipratropium, IV/oral steroids, IV MgSO4 (severe), Heliox, NIV, and rarely intubation

Prognosis

• Well-controlled asthma: Near-normal life expectancy
• In India, uncontrolled asthma is common (poor access, stigma, cost); frequent hospitalizations worsen QoL
• Asthma deaths are largely preventable with adequate ICS use

4. Community-Acquired Pneumonia (CAP)

Epidemiology in India

• Community: S. pneumoniae, H. influenzae, Klebsiella (especially in alcoholics, diabetics), atypicals
• Immunocompromised: P. jirovecii (in HIV), TB, fungi (Aspergillus, Cryptococcus)
• Post-influenza bacterial superinfection: S. aureus (including MRSA)

Clinical Features

• Fever, cough (productive), pleuritic chest pain, breathlessness
• Consolidation signs: Dullness, bronchial breathing, increased vocal fremitus
• Rapid onset (hours to days)
• Severity assessment: CURB-65 score (Confusion, Urea >7, RR ≥30, BP <90/60, Age ≥65) - widely used in India:
  • Score 0-1: Outpatient
  • Score 2: Hospitalize
  • Score ≥3: Consider ICU

Treatment

• Amoxicillin 500mg TID x 5 days OR
• Doxycycline (if atypical suspected) OR
• Azithromycin (if significant atypical burden, though resistance emerging in India)

• Beta-lactam (amoxicillin-clavulanate or ceftriaxone) + atypical coverage (azithromycin/doxycycline)
• Duration: 5-7 days

• Beta-lactam (ceftriaxone/cefotaxime) + macrolide OR respiratory fluoroquinolone
• If Klebsiella suspected (lobar consolidation, "currant-jelly sputum" in alcoholic/diabetic): carbapenem-based therapy
• If post-influenza with suspected S. aureus/MRSA: add vancomycin/linezolid

Prognosis

• Mortality: 5-10% for hospitalized non-ICU; 20-30% for severe CAP/ICU
• Gram-negative and MRSA pneumonia carry worse prognosis in Indian setting
• Non-resolving pneumonia (>4 weeks) requires TB exclusion, malignancy workup, unusual organisms

5. Interstitial Lung Disease (ILD) / Idiopathic Pulmonary Fibrosis (IPF)

Overview in India

• Post-TB fibrosis (extremely common, often confused with IPF)
• Hypersensitivity pneumonitis (HP) from agricultural dusts, bird/animal antigens, moulds
• Connective tissue disease-associated ILD (CTD-ILD): Rheumatoid arthritis, systemic sclerosis, dermatomyositis
• Silicosis/pneumoconiosis (stone quarry workers, mining - prevalent in Rajasthan, Jharkhand, Madhya Pradesh)
• Idiopathic Pulmonary Fibrosis (IPF)

Clinical Features

• Progressive exertional dyspnea (insidious onset over months to years)
• Dry, non-productive cough
• Bibasal fine end-inspiratory velcro crackles on auscultation
• Clubbing (especially in IPF)
• Radiologically: Bibasal reticulation, honeycombing on HRCT (UIP pattern in IPF)
• Restrictive pattern on spirometry: FVC <80%, FEV1/FVC normal or increased, reduced DLCO

IPF Prognosis

• Median survival: 3-5 years from diagnosis without treatment
• Poor prognostic factors: Pulmonary hypertension (PH) complicating IPF markedly worsens survival
  • IPF + PH: median survival < 1 year vs. 4-5 years without PH
  • 5-year survival with mPAP > 17 mmHg = 17%; vs. 62% with mPAP < 17 mmHg
• Murray & Nadel's Textbook of Respiratory Medicine

Treatment

• Antifibrotic therapy: Pirfenidone or Nintedanib - slows FVC decline; access limited and costly in India (government schemes partially subsidize)
• HP: Identify and remove the antigen; steroids; some cases progress despite treatment
• CTD-ILD: Immunosuppression (mycophenolate, azathioprine, cyclophosphamide in aggressive cases)
• Silicosis: No curative treatment; preventive (dust masks, water sprays in mines); compensation and disability
• Lung transplantation: Very limited availability in India; few specialized centers (Chennai, Delhi, Pune)

6. Lung Cancer

Epidemiology in India

• India's lung cancer incidence is rising, currently ~70,000 new cases/year
• Adenocarcinoma is the most common histological type in non-smokers (rising due to air pollution and cooking fumes in women)
• Squamous cell carcinoma more common in male smokers
• Small Cell Lung Cancer (SCLC) - strongly smoking-associated; aggressive biology
• Many Indian patients present at advanced stage (III/IV) due to late detection

Clinical Features

• Persistent cough, hemoptysis, chest pain, dyspnea
• Weight loss, anorexia, fatigue (systemic)
• Horner's syndrome, superior vena cava syndrome, hoarseness (recurrent laryngeal nerve)
• Pancoast tumor (apical): shoulder/arm pain, Horner's
• Paraneoplastic syndromes: SIADH (SCLC), hypercalcemia (SCC), Lambert-Eaton syndrome

Diagnosis

• HRCT chest, PET-CT for staging
• Bronchoscopy with biopsy, CT-guided FNAC
• EGFR, ALK, ROS1, PD-L1 testing - critical for targeted therapy; EGFR mutations more common in Indian adenocarcinoma patients (non-smoker females) than in Western populations (~25-30% of Indian adenocarcinomas)

Treatment

Prognosis

• 5-year survival: ~18% overall (all stages)
• Stage I resected NSCLC: ~60-70% 5-year survival
• Stage IV without driver mutation: Median OS ~12-18 months with modern chemo-immunotherapy
• Stage IV EGFR-mutant: Median OS ~38 months with osimertinib

7. Pulmonary Hypertension (PH)

Indian context

• Group 1 (Idiopathic PAH): Rare, but younger age of presentation seen in India
• Group 3 (PH due to lung disease/hypoxia): Very common - complicates COPD, IPF, post-TB fibrosis, and high-altitude living
• Group 4 (CTEPH): Thromboembolic PH - under-recognized

Features and Prognosis

• Progressive dyspnea, exertional syncope, right heart failure (edema, raised JVP, hepatomegaly)
• "Pulmonary hypertension independent of cause carries a poor prognosis and is typically diagnosed late when treatment is less effective" - Grainger & Allison's Diagnostic Radiology
• Group 1 PAH: Multiple pharmacological options available (PDE-5 inhibitors, endothelin antagonists, prostacyclins); Group 4: Pulmonary endarterectomy potentially curative

8. Bronchiectasis

• Post-TB bronchiectasis - most common cause
• Childhood infections (measles, pertussis, recurrent pneumonia) with inadequate treatment
• Immotile cilia syndrome, cystic fibrosis (lower prevalence but increasing recognition)

9. Obstructive Sleep Apnea (OSA)

Summary Comparison Table

Key India-Specific Considerations Across All Respiratory Diseases

1. TB must always be excluded first - it mimics everything from CAP to lung cancer to ILD
2. Biomass fuel exposure drives COPD in non-smoking rural women - a pattern not seen in the West
3. Air pollution (India has many cities in the world's top 10 most polluted) worsens asthma, COPD, and lung cancer
4. Nutritional status (malnutrition, low BMI) worsens TB outcomes and CAP severity
5. Late presentation is common for lung cancer and ILD due to lack of screening programs
6. Drug resistance in TB is a major programmatic challenge; NTEP has decentralized DR-TB care with 147+ centers
7. Cost and access barriers limit ICS use in asthma, antifibrotics in IPF, and targeted therapy in lung cancer
8. NIKSHAY (digital TB notification portal) mandates all TB case notification in India - government + private

1. TB - always exclude first; India has 26% of global burden; NTEP/DOTS is the backbone of management; MDR-TB is rising and requires 2nd/3rd line drugs for 18-24 months (or newer BPaL 6-month oral regimen)
2. COPD - 55 million patients; biomass fuel is the dominant Indian-specific driver in rural women; spirometry remains under-utilized; LABA/LAMA + smoking/fuel cessation is cornerstone of treatment
3. Asthma - 30 million affected; urban air pollution and allergen sensitization are key triggers; ICS compliance is the biggest treatment gap in India

• TB mimics everything - CAP, lung cancer, ILD, and pleural disease
• Post-TB sequelae (bronchiectasis, COPD, fibrosis, aspergilloma) create a distinct disease burden not seen in Western practice
• Non-smoking COPD from biomass fuel is a uniquely South Asian epidemiological pattern
• EGFR mutations are more common in Indian lung adenocarcinoma (~25-30%), making molecular testing essential before starting chemotherapy
• Late-stage presentation of lung cancer and ILD remains the norm due to absence of screening programs